PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Bioorganic Chemistry0 citations

An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibition

View Full Paper
XWXiuqi WangUniversity of Arkansas for Medical SciencesRDRosa Anna DeFilippisUniversity of California, San FranciscoHGHuimin GengUniversity of California, San Francisco

Key Points

  • The potent inhibitor shows significant effects in mv4-11 cells, supporting its potential clinical application.
  • Researchers observed that treatment resulted in a marked reduction of cell viability by 80% over 48 hours.
  • Detailed investigations explored mechanisms beyond flt3 signaling, aiming to unravel its broader impact.
  • This analysis may highlight new therapeutic strategies for targeting mv4-11 cells, but additional studies are essential.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69a760dfc6e9836116a2e091https://doi.org/10.1016/j.bioorg.2026.109601
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia2020 · 63 citations
  2. 2FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation2021 · 111 citations
  3. 3Cstf2t Regulates expression of histones and histone‐like proteins in male germ cells2018 · 25 citations
  4. 4Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells2021 · 15 citations
  5. 5An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia2022 · 14 citations